Takeda Pharmaceutical (TAK) Long-Term Deferred Tax (2017 - 2026)

Takeda Pharmaceutical's Long-Term Deferred Tax history runs 10 years deep, the most recent figure standing at $3.5 billion for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 43.34% year-over-year to $3.5 billion in Q1 2026; TTM through Mar 2026 was $3.5 billion, a 43.34% increase from a year earlier, with the FY2026 full-year figure at $3.6 billion, up 49.1% from the prior year.
• Long-Term Deferred Tax rose to $3.5 billion in Q1 2026 per TAK's latest filing, from $2.8 billion in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $3.5 billion in Q1 2026 and bottomed at $2.1 billion in Q4 2023.
• The 5-year median for Long-Term Deferred Tax is $2.7 billion (2024), against an average of $2.7 billion.
• Across the five-year window, Long-Term Deferred Tax fell 18.55% in 2023 and jumped 43.34% in 2026, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $2.5 billion in 2022, then retreated by 15.78% to $2.1 billion in 2023, then rose by 15.52% to $2.5 billion in 2024, then climbed by 12.23% to $2.8 billion in 2025, then increased by 25.4% to $3.5 billion in 2026.
• Per Business Quant, the three latest TAK Long-Term Deferred Tax figures stand at $3.5 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.6 billion (Q3 2025).